New prognostic indexes for overall survival in malignant mesothelioma treated with pemetrexed or best supportive care in the real world
Latest Information Update: 22 May 2015
Price :
$35 *
At a glance
- Drugs Pemetrexed (Primary)
- Indications Malignant-mesothelioma
- Focus Biomarker; Therapeutic Use
- 13 Apr 2015 Status changed from recruiting to completed as reported by UMIN.
- 15 Sep 2013 New trial record